BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38011391)

  • 21. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
    Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
    Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
    Portaccio E; Fonderico M; Iaffaldano P; Pastò L; Razzolini L; Bellinvia A; De Luca G; Ragonese P; Patti F; Brescia Morra V; Cocco E; Sola P; Inglese M; Lus G; Pozzilli C; Maimone D; Lugaresi A; Gazzola P; Comi G; Pesci I; Spitaleri D; Rezzonico M; Vianello M; Avolio C; Logullo FO; Granella F; Salvetti M; Zaffaroni M; Lucisano G; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2022 Sep; 79(9):869-878. PubMed ID: 35877104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.
    Ziemssen T; Rauer S; Stadelmann C; Henze T; Koehler J; Penner IK; Lang M; Poehlau D; Baier-Ebert M; Schieb H; Meuth S
    PLoS One; 2015; 10(9):e0138243. PubMed ID: 26393519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
    Abdollahpour I; Nedjat S; Mansournia MA; Eckert S; Weinstock-Guttman B
    Acta Neurol Scand; 2018 Oct; 138(4):308-314. PubMed ID: 29740825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis.
    Bieniek M; Altmann DR; Davies GR; Ingle GT; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1036-9. PubMed ID: 16793860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon Beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006643. PubMed ID: 20091602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
    Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic criteria for primary progressive multiple sclerosis: a position paper.
    Thompson AJ; Montalban X; Barkhof F; Brochet B; Filippi M; Miller DH; Polman CH; Stevenson VL; McDonald WI
    Ann Neurol; 2000 Jun; 47(6):831-5. PubMed ID: 10852554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
    Brown LJ; Li J; Brunner M; Snoke M; La HA
    J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Salter A; Thomas NP; Tyry T; Cutter GR; Marrie RA
    Mult Scler; 2018 Jun; 24(7):951-962. PubMed ID: 28524746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parental ethnicity associated with risk for multiple sclerosis: A population-based incident case-control study in Iran.
    Abdollahpour I; Nedjat S; Mansournia MA; Sahraian MA; Asgari N
    Mult Scler Relat Disord; 2018 Feb; 20():100-103. PubMed ID: 29353734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural history of primary progressive multiple sclerosis.
    Ebers GC
    Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disability accrual in primary and secondary progressive multiple sclerosis.
    Harding-Forrester S; Roos I; Nguyen AL; Malpas CB; Diouf I; Moradi N; Sharmin S; Izquierdo G; Eichau S; Patti F; Horakova D; Kubala Havrdova E; Prat A; Girard M; Duquette P; Grand'Maison F; Onofrj M; Lugaresi A; Grammond P; Ozakbas S; Amato MP; Gerlach O; Sola P; Ferraro D; Buzzard K; Skibina O; Lechner-Scott J; Alroughani R; Boz C; Van Pesch V; Cartechini E; Terzi M; Maimone D; Ramo-Tello C; Yamout B; Khoury SJ; La Spitaleri D; Sa MJ; Blanco Y; Granella F; Slee M; Butler E; Sidhom Y; Gouider R; Bergamaschi R; Karabudak R; Ampapa R; Sánchez-Menoyo JL; Prevost J; Castillo-Trivino T; McCombe PA; Macdonell R; Laureys G; Van Hijfte L; Oh J; Altintas A; de Gans K; Turkoglu R; van der Walt A; Butzkueven H; Vucic S; Barnett M; Cristiano E; Hodgkinson S; Iuliano G; Kappos L; Kuhle J; Shaygannejad V; Soysal A; Weinstock-Guttman B; Van Wijmeersch B; Kalincik T;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):707-717. PubMed ID: 37068931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.